DAFTAR PUSTAKA 1. Katno, Pramono S. Tingkat Manfaat dan ...

55

DAFTAR PUSTAKA

1. Katno, Pramono S. Tingkat Manfaat dan Keamanan Tanaman Obat dan Obat

Tradisional. Balai Penelitian Obat Tawangmangu, Fakultas Farmasi

Universitas Gajah Mada [press release]. Yogyakarta: Fakultas Farmasi UGM.

2. Faried A, Kurnia D, Faried L.S, Usman N, T. Miyazaki, Kato H. Anticancer

effects of gallic acid isolated from Indonesian herbal medicine, Phaleria

macrocarpa (Scheff.) Boerl, on human cancer cell lines. Int j oncol [Internet].

2007 [cited 2012 Nov 29];30(3): 605-13. Available from: Spandidos

Publications

3. Amit KT, Madhumita R, Bhattacharya RK. Natural products as inducers of

apoptosis: Implication for cancer therapy and prevention. Current Science

[Internet]. 2001 [cited 2012 Nov 29]; 80(11):1387-96. Available from: Indian

Institute of Science

4. Tazulakhova EB, Parshina OV, Guseva TS, Ershov FI. Russian experience

screening, analysis, and clinical application of novel interferon inducers. J

Interferon Cytokine Res [Internet]. 2001 [cited 2012 Nov 29]; 21(2): 65-73.

Available from: Marry Ann Liebert Inc. publisher

5. Stagg J. Phyllanthus. c2006 [updated 2006 Jun 17; cited 2013 Feb 7].

Available from: http://www.supplementnews.org/phyllanthus.html cited

17/6/06

6. Williams JE. Review of antiviral and immunomodulating properties of plants

of the Peruvian rainforest with a particular emphasis on Uña de Gato and

Sangre de Grando. Alternative Medicine Review [Internet]. 2001 [cited 2012

Nov 29];6(6):567-79. Available from: Thorne Research, Inc.

7. Ahmed N, Agrawal SS, Chattervedi S, Tabassum N. Hepatoprotective studies

on phyllanthus niruri on paracetamol induced liver cell damage in albino

http://www.supplementnews.org/phyllanthus.html%20cited%2017/6/06

http://www.supplementnews.org/phyllanthus.html%20cited%2017/6/06

56

mice. JK-Practtitioner [Internet]. 2005 [cited 2012 Nov 29]; 12(4):211-2.

Available from: Indian Medlars Centre

8. Bagalkotkar G, Sagineedu SR, Saad MS, Stanslas. Phytochemicals from

phyllanthus niruri linn and their pharmacological properties. Journal of

Pharmacy and Pharmacology [Internet]. 2006 [cited 2012 Nov 29]; 58(12):

1559-70. Available from: Wiley Online Library

9. Phyllanthus Introduction [Internet]. c2009 [updated 2009 Jun 2; cited 2012

Nov 29]. Available from: http://www.supplementnews.org/wiki/phyllanthus

10. Krithika R, Mohankumar R, Verma RJ. Shrivastav PS, Mohamad IL,

Gunasekaran P, et al. Isolation, characterization and antioxidative effect of

phyllanthin against CCl4-induced toxicity in HepG2 cell line. Chemico-

Biological Interactions Journal [Internet]. 2009 [cited 2012 Nov 29]; 181(3):

351-8. Available from: ScienceDirect

11. Setiawati A, Suyatna FD, Gan S. Pengantar Farmakologi dan Terapi. 5th

ed.

Jakarta: Departemen Farmakologi dan Terapeutik Fakultas Kedokteran

Universitas Indonesia; 2007.

12. Donatus IA. Toksikologi Dasar. 2nd

ed. Yogyakarta: Bagian Farmakologi dan

Farmasi Klinik Fakultas Farmasi Universitas Gajah Mada; 2005

13. Mehta N, Ozick LA, Gbadehan E, Sharma S, Tavalera F, Rice TD, et al.

Drug-Induced Hepatotoxicity [Internet]. c2012 [updated 2012 Jun 27; cited

2012 Nov 29]. Available from:

http://emedicine.medscape.com/article/169814-overview#aw2aab6b4

14. Katzung BG. Farmakologi Dasar dan Klinik. 10th

ed. Jakarta: Penerbit Buku

Kedokteran EGC; 2010

15. Underwood JC, Cross SS. General and Systematic Pathology. 5th

ed. London:

Churcill Livingstone; 2009

16. Kumar V, Cotran RS, Robbins SL. Buku Ajar Patologi. 7th

ed. Jakarta:

Penerbit Buku Kedokteran EGC; 2007

http://www.supplementnews.org/wiki/phyllanthus

http://emedicine.medscape.com/article/169814-overview#aw2aab6b4

57

17. Guyton AC, Hall JE. Buku Ajar Fisiologi Kedokteran. 11th

ed. Jakarta: EGC;

2007. 902-6

18. Moslen, MT. Toxic responses of the liver. In: Klaasen, CD, Editor. Casarett

and Doull’s toxicology the basic science of poisons. 6th

ed. New York: Mac

Graw Hill; 2001. 471-88

19. Parkinson A. Biotransformation of xenobiotics. In: Klaasen, CD, Editor.

Casarett and Doull’s toxicology the basic science of poisons. 6th

ed. New

York: Mac Graw Hill; 2001. 72-97

20. Patient UK. Liver Function Test [Internet]. c2010 [updated 2010 Feb 02, cited

2013 Jan 26]. Available from: http://www.patient.co.uk/health/Blood-Test-

Liver-Function-Tests.htm

21. Herrine KS, Navarro VJ. Liver Injury Caused by Drugs [Internet]. c2009

[updated 2013 Jan, cited 2013 Jan 26]. Available from:

http://www.merck.com/mmpe/sec03/ch024/ch024c.html

22. Liver function test. Wikipedia [online] c2009 [updated 2009 Oct 07, cited

2013 Jan 26] Available from: http://en.wikipedia.org/wiki/liver_function_test

23. Tim Penulis. Buku Ajar Ilmu Penyakit Dalam Jilid I. 3rd

ed cetakan ke-7.

Jakarta: Balai Penerbit FKUI; 2004. 226-7

24. Guyton AC, Hall JE. Buku Ajar Fisiologi Kedokteran. 11th

ed. Jakarta: EGC;

2007. 324-33

25. Schnellmann RG. Toxic responses of the kidney. In: Klassen CD. Casarett

and Doull’s toxicology the basic science of poisons. 6th

ed. New York: Mac

Graw Hill; 2001. 491-510

26. Hodgson E, Levi PE. Nephrotoxicity. In: Hodgson E, editor. A Textbook of

modern toxicology, 3rd

ed. New York: John Wiley & Sons; 2004. 273-5

27. Cotran RS. Ginjal dan sistem penyalurannya. In: Robbins SL, Kumar V. Staf

Pengajar Laboratorium Patologi Anatomik Fakultas Kedokteran Universitas

Airlangga, editor. Buku ajar patologi II. 4th

ed. Jakarta: EGC; 1995. 203-4

http://www.patient.co.uk/health/Blood-Test-Liver-Function-Tests.htm

http://www.patient.co.uk/health/Blood-Test-Liver-Function-Tests.htm

http://www.merck.com/mmpe/sec03/ch024/ch024c.html

http://en.wikipedia.org/wiki/liver_function_test

58

28. Underwood JCE. Sarjadi, editor. Patologi umum dan sistemik. 2nd

ed. Jakarta:

EGC; 2000

29. Ford-Martin PA, Best MA. Kidney Function Tests [Internet]. cited 2013 Jan

26. Available from: http://www.surgeryencyclopedia.com/Fi-La/Kidney-

Function-Tests.html

30. Tim Penulis. Buku Ajar Ilmu Penyakit Dalam Jilid II. 3rd

ed cetakan ke-2.

Jakarta: Balai Penerbit FKUI; 2004. 301

31. Lisdawati V. Mahkota Dewa, toksisitas, efek anti oksidan, dan efek anti-

kanker berdasarkan uji penapisan farmakologi [Internet]. c2002 [updated 2004

Jul 09, cited 2013 Jan 26]. Available from:

http://mahkotadewa.com/blog/2004/07/tinjauan-ilmiah-dra-vivi-lisdawati-

msi-apt/

32. Sumastuti R, Sonlimar M. Efek sitotoksik ekstrak buah dan daun Mahkota

Dewa terhadap sel hela. Yogyakarta: Farmakologi FK UGM; 2003

33. Selamat B, Benny I, Djoko H, Dwi P, Riwanto I. Pengaruh kombinasi ekstrak

mahkota dewa (phaleria macrocarpa) dengan doxorubicin dan

cyclophosphamide terhadap ekspresi VEGF dan indeks apoptosis tumor

adenokarsinoma mamma mencit C3H. (in-press).

34. Sulaksana J, Jayusman DI. Meniran, Budi Daya dan Pemanfaatan untuk Obat.

Cetakan I, Jakarta: Penebar Swadaya; 2004.

35. Taylor. Technical Data Report for Chanca Piedra. In: Herbal Secrets of The

Rainforest, 2nd

ed, Austin India: Sage Press, Inc; 2003

36. Mangan Y. Cara Bijak Menaklukkan Kanker. Sehat dengan Ramuan

Tradisional. Cetakan keempat revisi, Jakarta: Agro Media Pustaka; 2005.

37. Markom M, Hasan M, Daud WRW, Singh H, Jahim JM. Extraction of

hydrolisable tannins from Phyllanthus niruri Linn: effects of solvents and

extraction methods. Separation and Purification Technology [Internet]. 2007

[cited 2013 Jan 26]; 52(3): 487-96. Available from: ScienceDirect

http://www.surgeryencyclopedia.com/Fi-La/Kidney-Function-Tests.html

http://www.surgeryencyclopedia.com/Fi-La/Kidney-Function-Tests.html

http://mahkotadewa.com/blog/2004/07/tinjauan-ilmiah-dra-vivi-lisdawati-msi-apt/

http://mahkotadewa.com/blog/2004/07/tinjauan-ilmiah-dra-vivi-lisdawati-msi-apt/

59

38. Liu L, Lin H. Genus Phyllanthus for chronic hepatitis B virus infection. J

Viral Hepatitis [Internet]. 2001 [cited 2013 Jan 26]; 8(5): 358-62. Available

from: Wiley Online Library

39. Mustofa, Solikhah EN, Wahyuono S. In vitro and in vivo antiplasmodial

activity and cytotoxicity of extracts of Phyllanthus niruri Linn herbs

traditionally used to treat malaria in Indonesia. Southeast Asian J. Trop Med

Public Health [Internet]. 2007 [cited 2013 Jan 26]; 38(4): 609-15. Available

from: Index Medicus for South-East Asia Region

40. Taylor, L. Chanca Piedra. In: The Healing Power of Rainforest Herb. Carson

City: Raintree Nutrition, Inc; 2005

41. Ma’at S. Imunomodulator manfaat dan bahayanya. Dalam: Kusmita L,

Djatmika. Imunomodulator dan Perkembangannya. Prosiding Seminar

Nasional Farmasi Tahun 2010 Cetakan ketiga. Semarang: Penerbit STIFAR

Yayasan Farmasi; 2010

42. Sumaryanto W. Analisis Urea-Kreatinin Tikus Putih pasca Pemberian Ekstrak

Buah Mahkota Dewa dan Herba Pegagan. Jurnal Ilmu Kefarmasian Indonesia.

2008; 6(1): 35-40

43. Edhiatmi M. Pengaruh Pemberian Ekstrak Mahkota Dewa (Phaleria

papuana) Dosis Bertingkat terhadap Struktur Histologik Hepar Mencit

BALB/c. Semarang: Program Studi Pendidikan Kedokteran Universitas

Diponegoro;2006

44. Firdaus GI. Uji Toksisitas Akut Ekstrak Meniran (Phyllanthus niruri)

terhadap Hepar Mencit BALB/c. Semarang: Program Studi Pendidikan

Kedokteran Universitas Diponegoro; 2010

45. Alboneh SFH. Uji Toksisitas Akut Ekstrak Meniran (Phyllanthus niruri)

terhadap Ginjal Mencit BALB/c. Semarang: Program Studi Pendidikan

Kedokteran Universitas Diponegoro; 2010

46. Ali RB, Atangwho IJ, Kaur N, Abraika OS, Ahmad M, Mahmud R, et al.

Bioassay-guided antidiabetic study of Phaleria macrocarpa fruit extract.

60

Molecules [Internet]. 2012 [cited 2013 July 22]; 17(5): 4986-5002. Available

from: http://www.ncbi.nlm.nih.gov/pubmed/22547320

47. Gordon WP, Forte AJ, McMurtry RJ, Gal J. Hepatotoxicity and pulmonary

toxicity of pennyroyal oil and its constituent terpenes in the mouse.

Toxicology and Applied Pharmacology [Internet]. 1982 [cited 2013 July 22];

65(3): 413-24. Available from:

http://www.sciencedirect.com/science/article/pii/0041008X82903878

48. Authors. Terpenes. TCI America. Available from:

http://www.tcichemicals.com/eshop/en/us/category_index/00306/

http://www.ncbi.nlm.nih.gov/pubmed/22547320

http://www.sciencedirect.com/science/article/pii/0041008X82903878

http://www.tcichemicals.com/eshop/en/us/category_index/00306/

61

DOKUMENTASI PENELITIAN

62

OUTPUT ANALISIS SPSS 11.5 FOR WINDOWS

1. Kadar AST

Tabel 4. Kadar AST

Sampel Kontrol P1 P2 P3

A 269 425 152 263

B 209 767 200 231

C 299 279 196 227

D 260 190 165 348

E 452 231 185 222

Rata-

rata

297,8 378,4 179,6 258,2

a. Analisis Deskriptif

Descriptives

PERLAKUA Statistic Std. Error

KADAR K Mean 297,80 41,184

95% Confidence Interval for Mean

Lower Bound 183,45

Upper Bound 412,15

5% Trimmed Mean 294,17

Median 269,00

Variance 8480,700

Std. Deviation 92,091

Minimum 209

Maximum 452

Range 243

Interquartile Range 141,00

Skewness 1,541 ,913

Kurtosis 2,954 2,000

P1 Mean 378,40 104,948


Lower Bound 87,02

Upper Bound 669,78


63

Median 279,00

Variance 55070,800


Minimum 190

Maximum 767

Range 577


Skewness 1,545 ,913


P2 Mean 179,60 9,190


Lower Bound 154,08

Upper Bound 205,12


Median 185,00

Variance 422,300


Minimum 152

Maximum 200

Range 48


Skewness -,532 ,913

Kurtosis -1,887 2,000

P3 Mean 258,20 23,570


Lower Bound 192,76

Upper Bound 323,64


Median 231,00

Variance 2777,700


Minimum 222

Maximum 348

Range 126


Skewness 1,783 ,913


b. Analisis Analitik

1). Uji Normalitas

64

2). Uji Normalitas Setelah Data Ditransform dengan log-n

3). Uji One Way ANOVA

ANOVA

TRANS

Sum of

Squares df Mean Square F Sig.

Between Groups ,198 3 ,066 3,191 ,052

Within Groups ,331 16 ,021

Total ,528 19

Tests of Normality

,295 5 ,179 ,861 5 ,233

,264 5 ,200* ,841 5 ,167

,204 5 ,200* ,918 5 ,519

,297 5 ,171 ,769 5 ,044

PERLAKUA

K

P1

P2

P3

KADAR

Stat ist ic df Sig. Stat ist ic df Sig.

Kolmogorov -Smirnova

Shapiro-Wilk

This is a lower bound of the true signif icance.*.

Lillief ors Signif icance Correctiona.

Tests of Normality

,247 5 ,200* ,926 5 ,568

,221 5 ,200* ,935 5 ,629

,217 5 ,200* ,912 5 ,482

,297 5 ,172 ,798 5 ,077

PERLAKUA

K

P1

P2

P3

TRANS

Stat ist ic df Sig. Stat ist ic df Sig.

Kolmogorov -Smirnova

Shapiro-Wilk

This is a lower bound of the true signif icance.*.

Lillief ors Signif icance Correctiona.

65

2. Kadar ALT

Tabel 6. Kadar ALT


A 81 123 57 83

B 63 249 65 65

C 85 74 112 60

D 134 52 79 87

E 128 43 108 94

Rata-

rata

98,2 108,2 84,2 77,8


Descriptives


KADAR K Mean 98,20 13,926


Lower Bound 59,53

Upper Bound 136,87


Median 85,00

Variance 969,700


Minimum 63

Maximum 134

Range 71


Skewness ,295 ,913

Kurtosis -2,571 2,000

P1 Mean 108,20 37,830


Lower Bound 3,17

Upper Bound 213,23


Median 74,00

Variance 7155,700


66

Minimum 43

Maximum 249

Range 206


Skewness 1,583 ,913


P2 Mean 84,20 11,124


Lower Bound 53,32

Upper Bound 115,08


Median 79,00

Variance 618,700


Minimum 57

Maximum 112

Range 55


Skewness ,206 ,913

Kurtosis -2,768 2,000

P3 Mean 77,80 6,538


Lower Bound 59,65

Upper Bound 95,95


Median 83,00

Variance 213,700


Minimum 60

Maximum 94

Range 34


Skewness -,342 ,913

Kurtosis -2,416 2,000


1). Uji Normalitas

Tests of Normality

67

PERLAKUA

Kolmogorov-Smirnov(a) Shapiro-Wilk

Statistic df Sig. Statistic df Sig.

KADAR K ,264 5 ,200(*) ,883 5 ,325

P1 ,257 5 ,200(*) ,829 5 ,137

P2 ,231 5 ,200(*) ,890 5 ,357

P3 ,239 5 ,200(*) ,911 5 ,474

* This is a lower bound of the true significance. a Lilliefors Significance Correction


ANOVA

KADAR

Sum of


Between Groups 2816,600 3 938,867 ,419 ,742

Within Groups 35831,200 16 2239,450

Total 38647,800 19

3. Kadar Kreatinin

Tabel 8. Kadar Kreatinin


A 0,38 0,15 0,49 0,36

B 0,52 0,38 0,33 0,37

C 0,36 0,28 0,33 0,31

D 0,40 0,41 0,42 0,37

E 0,46 0,34 0,36 0,43

Rata-

rata

0,424 0,312 0,386 0,368

68


Descriptives


KADAR K Mean ,4240 ,02926


Lower Bound ,3428

Upper Bound ,5052

5% Trimmed Mean ,4222

Median ,4000

Variance ,004

Std. Deviation ,06542

Minimum ,36

Maximum ,52

Range ,16

Interquartile Range ,1200

Skewness ,849 ,913

Kurtosis -,666 2,000

p1 Mean ,3120 ,04598


Lower Bound ,1843

Upper Bound ,4397


Median ,3400

Variance ,011


Minimum ,15

Maximum ,41

Range ,26


Skewness -1,153 ,913

Kurtosis ,996 2,000

p2 Mean ,3860 ,03076


Lower Bound ,3006

Upper Bound ,4714


Median ,3600

Variance ,005


69

Minimum ,33

Maximum ,49

Range ,16


Skewness 1,019 ,913

Kurtosis -,265 2,000

p3 Mean ,3680 ,01908


Lower Bound ,3150

Upper Bound ,4210


Median ,3700

Variance ,002


Minimum ,31

Maximum ,43

Range ,12


Skewness ,229 ,913



1). Uji Normalitas

Tests of Normality

PERLAKUA

Kolmogorov-Smirnov(a) Shapiro-Wilk

Statistic df Sig. Statistic df Sig.

KADAR K ,243 5 ,200(*) ,922 5 ,544

p1 ,207 5 ,200(*) ,917 5 ,513

p2 ,247 5 ,200(*) ,867 5 ,254

p3 ,281 5 ,200(*) ,927 5 ,579

* This is a lower bound of the true significance. a Lilliefors Significance Correction


ANOVA

KADAR

Sum of


70

Between Groups ,033 3 ,011 2,030 ,150

Within Groups ,086 16 ,005

Total ,118 19

DAFTAR PUSTAKA 1. Katno, Pramono S. Tingkat Manfaat dan ...

Documents

Transcript of DAFTAR PUSTAKA 1. Katno, Pramono S. Tingkat Manfaat dan ...